163 related articles for article (PubMed ID: 17322463)
21. Crohn's disease: Adalimumab improves quality of life.
Papadakis KA
Nat Rev Gastroenterol Hepatol; 2009 Apr; 6(4):200-1. PubMed ID: 19347008
[No Abstract] [Full Text] [Related]
22. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients.
Díaz-Llopis M; Salom D; Garcia-de-Vicuña C; Cordero-Coma M; Ortega G; Ortego N; Suarez-de-Figueroa M; Rio-Pardo MJ; Fernandez-Cid C; Fonollosa A; Blanco R; Garcia-Aparicio AM; Benitez-Del-Castillo JM; Olea JL; Arevalo JF
Ophthalmology; 2012 Aug; 119(8):1575-81. PubMed ID: 22525047
[TBL] [Abstract][Full Text] [Related]
23. Retrospective analysis of children with uveitis treated with infliximab.
Tugal-Tutkun I; Ayranci O; Kasapcopur O; Kir N
J AAPOS; 2008 Dec; 12(6):611-3. PubMed ID: 18930672
[TBL] [Abstract][Full Text] [Related]
24. A three-centre experience with adalimumab for the treatment of non-infectious uveitis.
Dobner BC; Max R; Becker MD; Heinz C; Veltrup I; Heiligenhaus A; Barisani-Asenbauer T; Mackensen F
Br J Ophthalmol; 2013 Feb; 97(2):134-8. PubMed ID: 23212204
[TBL] [Abstract][Full Text] [Related]
25. The effectiveness of adalimumab treatment for non-infectious uveitis.
Hasegawa E; Takeda A; Yawata N; Sonoda KH
Immunol Med; 2019 Jun; 42(2):79-83. PubMed ID: 31315546
[TBL] [Abstract][Full Text] [Related]
26. Uveitis Reactivation in Children Treated With Tumor Necrosis Factor Alpha Inhibitors.
Lerman MA; Lewen MD; Kempen JH; Mills MD
Am J Ophthalmol; 2015 Jul; 160(1):193-200.e1. PubMed ID: 25892124
[TBL] [Abstract][Full Text] [Related]
27. Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial.
Suhler EB; Lowder CY; Goldstein DA; Giles T; Lauer AK; Kurz PA; Pasadhika S; Lee ST; de Saint Sardos A; Butler NJ; Tessler HH; Smith JR; Rosenbaum JT
Br J Ophthalmol; 2013 Apr; 97(4):481-6. PubMed ID: 23376607
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of infliximab, adalimumab and golimumab for non-infectious refractory uveitis in adults.
Borrás-Blasco J; Casterá DE; Cortes X; Abad FJ; Rosique-Robles JD; Mallench LG
Int J Clin Pharmacol Ther; 2015 May; 53(5):377-90. PubMed ID: 25345430
[TBL] [Abstract][Full Text] [Related]
29. Sustained efficacy and safety of adalimumab in psoriasis treatment: a retrospective study of 49 patients with and without a history of TNF-alpha antagonist treatment.
Van L; Modi SV; Yang DJ; Hsu S
Arch Dermatol; 2008 Jun; 144(6):804-6. PubMed ID: 18559778
[No Abstract] [Full Text] [Related]
30. Psoriatic arthritis and chronic lymphoedema: treatment efficacy by adalimumab.
Tong D; Eather S; Manolios N
Clin Rheumatol; 2009 Nov; 28(11):1349-50. PubMed ID: 19693641
[TBL] [Abstract][Full Text] [Related]
31. TNF inhibitors for uveitis: balancing efficacy and safety.
Cunningham ET; Zierhut M
Ocul Immunol Inflamm; 2010 Dec; 18(6):421-3. PubMed ID: 21091055
[No Abstract] [Full Text] [Related]
32. Infliximab-induced acute hepatitis during Crohn's disease therapy: absence of cross-toxicity with adalimumab.
Haennig A; Bonnet D; Thebault S; Alric L
Gastroenterol Clin Biol; 2010 Sep; 34(8-9):e7-8. PubMed ID: 20189334
[No Abstract] [Full Text] [Related]
33. Inhibition of tumor necrosis factor alpha and ankylosing spondylitis.
Asli B; Wechsler B; Lemaître C
N Engl J Med; 2003 Jan; 348(4):359-61; author reply 359-61. PubMed ID: 12540654
[No Abstract] [Full Text] [Related]
34. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey.
Foeldvari I; Nielsen S; Kümmerle-Deschner J; Espada G; Horneff G; Bica B; Olivieri AN; Wierk A; Saurenmann RK
J Rheumatol; 2007 May; 34(5):1146-50. PubMed ID: 17343318
[TBL] [Abstract][Full Text] [Related]
35. Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database.
Wendling D; Joshi A; Reilly P; Jalundhwala YJ; Mittal M; Bao Y
Curr Med Res Opin; 2014 Dec; 30(12):2515-21. PubMed ID: 25252590
[TBL] [Abstract][Full Text] [Related]
36. [Adalimumab in Crohn's disease - data from real life].
López San Román A; Van Domselaar M; Garrido E
Rev Esp Enferm Dig; 2008 Nov; 100(11):671-5. PubMed ID: 19159169
[No Abstract] [Full Text] [Related]
37. Uncovering the risks of immunosuppressive therapy in patients with uveitis.
Goldstein DA
Arch Ophthalmol; 2009 Jun; 127(6):799-800. PubMed ID: 19506201
[No Abstract] [Full Text] [Related]
38. Commentary: infliximab or adalimumab in Crohn's disease?
Sprakes MB; Hamlin PJ
Aliment Pharmacol Ther; 2012 Aug; 36(4):398. PubMed ID: 22803644
[No Abstract] [Full Text] [Related]
39. Anti-TNFalpha therapy in a rare case of Crohn's disease: still a panacea.
Verburg R; Zelissen P; Rothova A; Siersema PD; Oldenburg B
Inflamm Bowel Dis; 2008 Oct; 14(10):1457-60. PubMed ID: 18383178
[No Abstract] [Full Text] [Related]
40. Letter: infliximab and adalimumab in the management of Crohn's disease--are they really comparable?
Lopez-Sanroman A; Gisbert JP
Aliment Pharmacol Ther; 2012 Sep; 36(5):498-9. PubMed ID: 22860615
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
